An analysis of oral microbial flora by T-RFLP in patients undergoing hematopoietic stem cell transplantation
An analysis of oral microbial flora by T-RFLP in patients undergoing hematopoietic stem cell transplantation
复制标题
T-RFLP分析造血干细胞移植患者口腔微生物菌群
DOI：
10.1007/s12185-020-02958-y
复制
发表时间：
2020
影响因子：
2.1
通讯作者：
Onizuka Makoto
中科院分区：
文献类型：
--
作者：
Takahashi Miho;Toyosaki Masako;Matsui Keiko;Machida Shinichiro;Kikkawa Eri;Ota Yoshihide;Kaneko Akihiro;Ogawa Yoshiaki;Ando Kiyoshi;Onizuka Makoto
尽管造血干细胞移植（HSCT）程序已得到改进，但口腔粘膜炎（OM）仍然是预处理方案的严重并发症。我们采用基于16 S rRNA基因的末端限制性片段长度多态性（T-RFLP）分析，对19例连续行HSCT的患者进行OM严重程度与口腔细菌植物群改变之间的相关性研究。在移植前、粘膜炎高峰期和移植后收集口腔样品。将每个时间点的T-RFLP图谱构建成X-Y矩阵，并计算时间点之间的距离。与对照组相比，重度和中度OM患者的口腔细菌植物群从HSCT前到粘膜炎高峰的变化更大（分别为p= 0.031和0.016）。此外，严重的粘膜炎与移植前发热时间延长、最大C反应蛋白水平升高以及阿片类药物治疗和静脉高营养时间延长显著相关。这些发现表明，粘膜炎的严重程度与口腔细菌植物群的变化幅度有关。这一新的发现可能有助于推进HSCT后OM的预防或治疗策略。
Even though the hematopoietic stem cell transplantation (HSCT) procedure has been improved, oral mucositis (OM) is still a severe complication of the conditioning regimen. We investigated the association between OM severity and the alteration of oral bacterial flora using 16S rRNA gene-based terminal restriction fragment length polymorphism (T-RFLP) analysis in 19 consecutive patients undergoing HSCT. Oral samples were collected at pre-transplantation, at the peak of mucositis and post-engraftment. T-RFLP profiles for each timepoint were constructed into anX–Ymatrix, and the distances between timepoints were calculated. Patients with severe and moderate OM had larger changes in their oral bacterial flora from before HSCT to peak of mucositis than controls (p= 0.031 and 0.016, respectively). Moreover, severe mucositis was significantly associated with an extended period of fever until engraftment, high maximum C-reactive protein levels, and prolonged periods of opioid treatment and intravenous hyper-alimentation. These findings suggest that mucositis severity is associated with the magnitude of change in the oral bacterial flora. This novel finding may help advance strategies for the prevention or treatment of OM after HSCT.